SCHEMBL14009258

SCHEMBL14009258

COc1ccc(NC(=O)c2ccc(C(=O)Nc3ccc(-c4ncn(C)n4)cc3)s2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ CA12 O43570 2/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA9 Q16790 2/20 0.41
▸ F10 P00742 3/20 0.41
▸ MAPK11 Q15759 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ PLAU P00749 1/20 0.40
▸ TP53 P04637 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ MAPT P10636 4/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14009158 0.80 NPC1 (0.54) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009284 0.79 CA1 (0.50) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009185 0.78 IMPDH2 (0.54) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009167 0.77 MAPT (0.49) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009231 0.77 MAPT (0.52) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009289 0.76 LMNA (0.48) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009015 0.76 MAPT (0.46) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009236 0.76 SMN1; SMN2 (0.48) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009006 0.76 SMN1; SMN2 (0.48) LMNASMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL14009239 0.76 RAB9A (0.56) LMNASMN1; SMN2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-7446195-B2 High affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION (US) 2008-11-04 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands SCHERING CORPORATION 2007-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043045-A1 Novel high affinity thiophene-based and furan-based kinase ligands CDKL2, CDK2, CDKL1 LMNA 3745/4885SMN1; SMN2 2211/4885KDM4E 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback